Trial Profile

Phase IB open label study to assess the safety, pharmacokinetics and clinical activity of Acelarin (NUC-1031) given on days 1 & 8 with carboplatin on day 1, every three weeks for 6 cycles in participants diagnosed with recurrent ovarian cancer.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fosgemcitabine palabenamide (Primary) ; Carboplatin
Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
Focus Adverse reactions
Acronyms ProGem2

19 Mar 2021 Results published in the Clinical Cancer Research
04 Jun 2019 Results assessing the anticancer activity in patients with advanced ovarian and biliary tract cancers treated with NUC-1031 and a platinum agent using PRO-002 and ABC-08 trial presented at the 55th Annual Meeting of the American Society of Clinical Oncology
12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com